|
Summary Information: UroGen Pharma Ltd. Ordinary Shares NASDAQ:URGN |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
__The following are links to various summary and news pages for __UroGen Pharma Ltd. Ordinary Shares [ URGN ]. __Note: Some Links might not have information for the company. |
|